Enigma, GSK Sign Infectious Disease Testing Pact | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enigma Diagnostics said today that it has inked a supply and commercialization agreement with GlaxoSmithKline covering its PCR technologies in Europe, India, Brazil, and Russia.

Under the agreement, Enigma will develop respiratory infectious disease tests for use on its Enigma ML PCR-based platform and it will give GSK the right to market the tests and develop more based on the same platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.